Scinopharm Taiwan (TPE:1789) Cash per Share: NT$4.42 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1789 Scinopharm Taiwan Ltd TPE:1789
69 GF Score
Price NT$18.60
GF Value NT$20.05
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Cash per Share?

Scinopharm Taiwan TPE:1789 -2.87% 69 Cash per Share is NT$4.42 as of Jun. 2026. GuruFocus rates TPE:1789 with a GF Score™ of 69/100 and a GF Value™ of NT$20.05 (Fairly Valued). The stock has 8 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Scinopharm Taiwan's Cash per Share for the quarter that ended in Jun. 2026 was NT$4.42.

Scinopharm Taiwan  (TPE:1789) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Scinopharm Taiwan Cash per Share Related Terms

Scinopharm Taiwan Cash per Share Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Cash per Share Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.23 5.50 5.00 5.27 3.93

Scinopharm Taiwan Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.91 3.61 3.93 4.13 4.42
TPE:1789
69GF Score
Scinopharm Taiwan Ltd TPE:1789
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Scinopharm Taiwan's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=3110.164/791
=3.93

Scinopharm Taiwan's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=3498.583/791
=4.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of NT$4.42 mean?
Scinopharm Taiwan (TPE:1789) has a Cash per Share of NT$4.42 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Cash per Share too high?
Scinopharm Taiwan's current Cash per Share is NT$4.42. Overall, Scinopharm Taiwan has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Cash per Share compare to ZTS?
Scinopharm Taiwan's Cash per Share of NT$4.42 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Drug Manufacturers company?
A good Cash per Share depends on the Drug Manufacturers industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Cash per Share is NT$4.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.05, compared to a current price of NT$18.60 — trading 7.2% below its estimated fair value. The current Cash per Share is NT$4.42. Scinopharm Taiwan's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Cash per Share is NT$4.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$18.60 is trading 7.2% below its estimated GF Value™ of NT$20.05. GuruFocus considers Scinopharm Taiwan to be Fairly Valued.

Key valuation signals for TPE:1789:

  • Cash per Share: NT$4.42
  • GF Value™: NT$20.05 vs. price of NT$18.60 (7.2% below fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
69GF Score

Get the complete analysis for TPE:1789

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.60
Price
NT$20.05
GF Value